Text
In partnership with leading research institutions, Microba launched the world’s first NATA-accredited metagenomic diagnostic test in 2022, capable of identifying 175 gastrointestinal pathogens in a single at-home analysis.
With an $87.33 million market capitalisation, the company has established strategic collaborations with Sonic Healthcare and Ginkgo Bioworks to develop a novel drug discovery program targeting autoimmune conditions. Recognised as AusBiotech’s ‘Emerging Company of the Year’ in 2018, Microba is strengthening Queensland’s position in microbiome research through significant partnerships with institutions including Queensland University of Technology.
With an $87.33 million market capitalisation, the company has established strategic collaborations with Sonic Healthcare and Ginkgo Bioworks to develop a novel drug discovery program targeting autoimmune conditions. Recognised as AusBiotech’s ‘Emerging Company of the Year’ in 2018, Microba is strengthening Queensland’s position in microbiome research through significant partnerships with institutions including Queensland University of Technology.
